Press Releases

• 08/19/2011
  Mersana Therapeutics to Participate in BioPharm America and UBS Global Life Sciences Conferences
• 04/20/2011
  Mersana Therapeutics Appoints Michael A. Metzger as EVP & COO
• 03/25/2011
  Mersana Therapeutics Initiates Phase 1b Extension Study of XMT-1001 in Gastric Cancer and Non-Small Cell Lung Cancer

• 09/29/2010
  Mersana Therapeutics Appoints Nicholas Bacopoulos President and Chief Executive Officer
• 06/23/2010
  Mersana Initiates Phase 1 Clinical Trial for XMT-1107 in Oncology
• 04/20/2010
  Mersana Therapeutics Presents Data Demonstrating XMT-1001 Substantially Accumulates in Tumor and Results in Significantly Prolonged Drug Exposure
• 04/13/2010
  Mersana Enters Research and Exclusive License Agreement with Teva Pharmaceuticals for the Development and Commercialization of XMT-1107

• 11/17/2009
  Mersana Therapeutics Provides Clinical Update from Ongoing Phase 1 Study of XMT-1001 in Patients with Advanced Solid Tumors
• 11/12/2009
  Mersana Therapeutics Publishes Review Article Detailing Advantages of it Lead Cancer Compound in Journal of Advanced Drug Delivery Reviews
• 06/01/2009
  Mersana Reports Preliminary Phase 1 Results of XMT-1001 in Patients with Advanced Solid Tumors
• 04/19/2009
  Mersana's Second Development Candidate, XMT-1107, Shows Superior Pharmacokinetics and Anti-Tumor Activity in Studies Presented at American Association of Cancer Research Meeting

• 04/14/2008
  Mersana's Second Development Candidate, XMT-1107, Shows Superior Pharmacokinetics and Anti-Tumor Activity in Studies Presented at American Association of Cancer Research Meeting
• 02/12/2008
  Mersana Therapeutics, Inc. Appoints Chief Scientific Officer, Timothy B. Lowinger, Ph.D.
• 01/03/2008
  Mersana Therapeutics Appoints C. Boyd Clarke Chairman of the Board of Directors

• 10/24/2007
  Mersana Therapeutics Reports Phase I Results for XMT-1001 in Patients with Solid Tumors at AACR-NCI-EORTC International Conference
• 07/12/2007
  Mersana Therapeutics, Inc. Appoints Pharmaceutical Industry Veteran Nicholas G. Bacopoulos, Ph.D. to Board of Directors
• 05/30/2007
  Mersana Therapeutics, Inc. Initiates Phase I Trial of Anti-Cancer Agent, XMT-1001, in Solid Tumors
• 04/13/2007
  Mersana Therapeutics, Inc. to Present Preclinical Data on XMT-1001 at American Association of Cancer Research Annual Meeting

• 11/08/2005
  Mersana Therapeutics, Inc. Completes $21 Million Financing